Initial experiences with serum alkaline DNase activity in monitoring the effects of therapy for carcinoma of the uterine cervix.
The objective was to evaluate if variations in serum alkaline DNase activity (SADA) can predict the effects of therapy in women with early stages of primary cervical carcinoma. 29 out of 33 patients had no evidence of disease after therapy. Only 5 out of the 29 women showed increased SADA levels after therapy compared with the pretreatment SADA value. Of the 4 women with evidence of disease after therapy, 3 had unchanged or decreased SADA levels. We conclude that serum alkaline DNase activity seems to have little to offer in predicting the effects of treatment in stage I and stage II cervical carcinoma.
Avall Lundqvist
E H
EH
Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden.
Sjövall
K
K
Eneroth
P H
PH
D003851:Deoxyribonucleases / Q000097:blood*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D013997:Time Factors; D014594:Uterine Neoplasms / Q000201:enzymology / Q000473:pathology / Q000628:therapy*
D003851:Deoxyribonucleases